Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Accelerated Phase 2Blast Crisis 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Leukemia, Biphenotypic, Acute 1

Interventions

Cyclophosphamide 21Cytarabine 15blinatumomab 13fludarabine 12Azacitidine 10venetoclax 9fludarabine phosphate 9Blood Specimen Collection 8Methotrexate 7Lenalidomide 7Dexamethasone 7Rituximab 6Mercaptopurine 6Daunorubicin 6Vincristine 5daratumumab 4Whole-Body Irradiation 4Melphalan 4Etoposide 4Busulfan 4obinutuzumab 3Radiotherapy 3Neoadjuvant Therapy 3Maintenance 3Liquid Biopsy 3Immunotherapy, Adoptive 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Drug Therapy 3Doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasm, Residual × N,N-dicyclohexyl-isoborneol-10-sulfonamide × Clear all
NCT02458014 2025-09-23

Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

M.D. Anderson Cancer Center

Phase 2 Completed
36 enrolled
Lymphoid

Burkitt Lymphoma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡